Another trial is currently evaluating the combination of tipifarnib and the PI3K inhibitor alpelisib in R/M HNSCC with HRAS and PIK3CA alterations (NCT04997902) (clinicaltrials.gov). Here, PIK3CA is linked to head and neck squamous cell carcinoma.